Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to $17000.0.

  • Relay Therapeutics' Cash from Financing Activities fell 9999.22% to $17000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $221.2 million, marking a year-over-year decrease of 2404.05%. This contributed to the annual value of $270.2 million for FY2024, which is 67735.16% up from last year.
  • Per Relay Therapeutics' latest filing, its Cash from Financing Activities stood at $17000.0 for Q3 2025, which was down 9999.22% from $800000.0 recorded in Q4 2024.
  • Relay Therapeutics' Cash from Financing Activities' 5-year high stood at $384.0 million during Q4 2021, with a 5-year trough of $17000.0 in Q3 2025.
  • Over the past 5 years, Relay Therapeutics' median Cash from Financing Activities value was $2.0 million (recorded in 2022), while the average stood at $57.8 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first skyrocketed by 68563571.43% in 2021, then tumbled by 9999.22% in 2025.
  • Over the past 5 years, Relay Therapeutics' Cash from Financing Activities (Quarter) stood at $384.0 million in 2021, then crashed by 99.7% to $1.2 million in 2022, then surged by 1779.76% to $21.9 million in 2023, then tumbled by 96.35% to $800000.0 in 2024, then tumbled by 97.88% to $17000.0 in 2025.
  • Its Cash from Financing Activities stands at $17000.0 for Q3 2025, versus $800000.0 for Q4 2024 and $218.9 million for Q3 2024.